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been associated with massive outbreaks; therefore it is necessary
to carry out active surveillance to monitor Dengue virus epidemi-
ology. Further study on pathogenecity of Dengue virus 1 as well as
other serotypes circulating in this region is in scope of this study.
http://dx.doi.org/10.1016/j.ijid.2016.02.921
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Background: Co-circulationof Japanese encephalitis Virus (JEV)
and West Nile Virus (WNV) has been accounted in India. Both
viruses are antigenically related and belong to the Japanese
encephalitis (JE) serocomplex. Recently, the Government of India
introduced the live attenuated JE vaccine SA 14-14-2 in routine
immunization program for children and mass vaccination cam-
paign among adults in highly JE endemic areas of Assam, Northeast
India. However, the protection elicited by the JE vaccine against
the circulating JEV and WNV in this region have not been stud-
ied. Thus, we investigated whether a single dose of this vaccine
provided protection against local JEV and WNV isolates in animal
model.
Methods & Materials: Eight groups (n=6) of four-six week old
Swiss albino mice were inoculated sub-cutaneously with the JE
vaccine. Four weeks post immunization, three mice groups were
challenged intra-peritoneally with three JEV and four WNV each
comprising of both archival and circulating strains. Onemice group
served as a control with no virus challenge. Micewere observed for
21 days.
Results: Theprotection rates against three JEV strains (genotype
III) were 100%. However, we noticed limited protection against the
fourWNV stains (Lineage V). But, interestingly, the protection rates
against archival WNV strains 804994 and circulating WNIRGC07
were 50% and 33.33% respectively. Whereas, no protection was
conferred by the vaccine to WNV archival G22886 and circulating
WNIRTC08 strains.
Conclusion: The study showed total protection against JEV
strains which may be due to the same genotype of the vaccine
(Genotype III) as that of the local JEV strains. However, JEV vaccine
was found to elicit partial cross protection to a circulating WNV
strain which was reported to be a variant. It is noteworthy that no
protection was observed against the other circulating WNV strain.
Thus for immunization strategies, limited cross protection against
heterologous viruses of the JE serocomplex must be considered.
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Background: WHO has identiﬁed Dengue as the fastest spread-
ingmosquito-borne disease in theworld. Approximately 96million
people develop clinical Dengue annually, of which 1 in every 200
proceeds to develop potentially fatal Dengue haemorrhagic fever
and/or shock syndrome (DHF/DSS). Depending on the availability
of appropriate supportive treatment, the case-fatality rate varies
from 3.5% to 50%. The debilitating and painful nature of the disease,
together with the lack of an accurate method to predict DHF/DSS,
resulted in unnecessary over-hospitalisation. The situation iswors-
ened during epidemic years, in both developed (e.g. Singapore in
2004/2005) anddevelopingcountries (e.g. India in2015) alike. Elec-
tive surgeries and non-emergency admissions had to be cancelled
to release health resources for Dengue inpatients. Our laboratory
previously discovered a panel of novel serum biomarkers that
can predict DHF/DSS with a sensitivity and speciﬁcity of 90% and
91%, respectively. As majority of Dengue-endemic countries are
developing countries, we sought to evaluate how test performance
wouldbe affectedbyusing only onebiomarker (BM1), so as tomake
the test more affordable.
Methods & Materials: 109 Dengue patients were enrolled from
the Colombo South Teaching Hospital and National Hospital of Sri
Lanka. The study was approved by the Ethics Review Committee
of the University of Sri Jayawardanapura, and all patients provided
informedconsent. Bloodsampleswerecollectedwhensubjectsﬁrst
presented themselves at the hospitals. Serum BM1 concentration
was measured using a quantitative ELISA developed in-house. All
statistical analyses were performed using R version 3.1.2.
Results: 60 subjects were diagnosed with DHF while 49 had
classical Dengue fever. Based on only serum BM1 concentration,
the performance of the test to predict DHF/DSSwas as follows: sen-
sitivity – 73.3%, speciﬁcity – 77.6%, positive predictive value (PPV)
– 80.0%, and negative predictive value (NPV) – 70.4%.
Conclusion: While performance of the BM1 prognostic test (on
Sri Lankan patients) could not match that of the panel prognostic
test (on Singapore patients), there were considerable improve-
ments in speciﬁcity and PPV over current clinical practices used
(in Singapore) to determine which Dengue patients to hospitalise
(speciﬁcity: ≤55%; PPV: ≤34%).
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